PMID- 31814904
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1943-8141 (Print)
IS  - 1943-8141 (Electronic)
IS  - 1943-8141 (Linking)
VI  - 11
IP  - 11
DP  - 2019
TI  - LncRNA DLX6-AS1 promotes laryngeal squamous cell carcinoma growth and invasion 
      through regulating miR-376c.
PG  - 7009-7017
AB  - Accumulating evidence showed that lncRNAs play important roles in tumour 
      development. Recently, a novel lncRNA DLX6-AS1 was found to be overexpressed in 
      some tumors such as lung adenocarcinoma, renal cell carcinoma and hepatocellular 
      carcinoma. However, the functional roles of DLX6-AS1 in laryngeal squamous cell 
      carcinoma (LSCC) are still unclear. In the study, we showed that the expression 
      level of DLX6-AS1 was upregulated in the LSCC samples compared to the 
      noncancerous tissues. By using CCK-8 analysis, we demonstrated that knockdown 
      expression of DLX6-AS1 suppressed the Hep2 cell growth. DLX6-AS1 knockdown 
      inhibited the Hep2 cell cycle and invasion. MiR-376c was identified to have the 
      complementary binding sites with the DLX6-AS1. By luciferase reporter assay, we 
      indicated that overexpression of miR-376c inhibited the luciferase activity of 
      wild-type DLX6-AS1, but it failed to suppress luciferase activity of mutated one. 
      DLX6-AS1 knockdown enhanced the expression of miR-376c in the Hep2 cell. 
      Moreover, we showed that the expression level of miR-376c was lower in the LSCC 
      samples than in the noncancerous tissues and the expression of miR-376c was 
      negatively correlated with expression of DLX6-AS1 in LSCC tissues. Ectopic 
      expression of miR-376c suppressed cell proliferation, cycle and invasion of LSCC 
      cell. DLX6-AS1 knockdown suppressed cell proliferation, cycle and invasion via 
      regulating miR-376c expression. These data proved that lncRNA DLX6-AS1 might play 
      as an oncogene in LSCC development and tumorigenesis.
CI  - AJTR Copyright (c) 2019.
FAU - Yang, Qingjun
AU  - Yang Q
AD  - Department of Otolaryngology, Head and Neck Surgery, Zhoukou Central Hospital 
      Zhoukou 466000, Henan, China.
FAU - Sun, Jin
AU  - Sun J
AD  - Department of Otolaryngology, Head and Neck Surgery, The First Affiliated 
      Hospital of Zhengzhou University Zhengzhou 450052, Henan, China.
FAU - Ma, Yifei
AU  - Ma Y
AD  - Department of Otorhinolaryngology, Affiliated Hospital of Guizhou Medical 
      University Guiyang 550004, Guizhou, China.
FAU - Zhao, Chunjie
AU  - Zhao C
AD  - Department of Otolaryngology, Head and Neck Surgery, Zhoukou Central Hospital 
      Zhoukou 466000, Henan, China.
FAU - Song, Jijun
AU  - Song J
AD  - Department of Otolaryngology, Head and Neck Surgery, Zhoukou Central Hospital 
      Zhoukou 466000, Henan, China.
LA  - eng
PT  - Journal Article
DEP - 20191115
PL  - United States
TA  - Am J Transl Res
JT  - American journal of translational research
JID - 101493030
PMC - PMC6895517
OTO - NOTNLM
OT  - DLX6-AS1
OT  - Laryngeal squamous cell carcinoma
OT  - lncRNA
OT  - miR-376c
COIS- None.
EDAT- 2019/12/10 06:00
MHDA- 2019/12/10 06:01
PMCR- 2019/11/15
CRDT- 2019/12/10 06:00
PHST- 2019/07/25 00:00 [received]
PHST- 2019/09/01 00:00 [accepted]
PHST- 2019/12/10 06:00 [entrez]
PHST- 2019/12/10 06:00 [pubmed]
PHST- 2019/12/10 06:01 [medline]
PHST- 2019/11/15 00:00 [pmc-release]
PST - epublish
SO  - Am J Transl Res. 2019 Nov 15;11(11):7009-7017. eCollection 2019.